Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal

Core Insights - Eli Lilly has increased its share value by over a third in 2025, largely due to strong sales of its weight-loss drugs [1][5] - The company announced a price reduction for its weight-loss drug Zepbound, following a deal with the Trump administration aimed at lowering drug costs [3][8] Pricing Details - The price for Zepbound will decrease by $50 for doses of 2.5, 7.5, 10, 12.5, and 15 milligrams, and by $100 for the 5-milligram dose, with prices ranging from $299 to $449 [2][8] - Starting next April, Zepbound and the obesity pill Orforglipron will be available for no more than $50 a month for Medicare recipients, pending FDA approval [4] Political Context - The decision to lower prices comes amid increasing political pressure for more affordable weight-loss drugs [3] - This pricing strategy follows a White House meeting where plans were discussed to enhance the accessibility of Lilly's weight-loss medications [3][4]